Onco Actu du 12 mai 2016

	3.1.1 Tabac - e-cigs
Smoke out [Nature News & Comment] Scientists should unite over electronic-cigarette regulation, or big tobacco will step in.
	3.2 Prévention - Obésité
BMI categories may need adjusting, argue researchers [NHS Choices] This cohort study compared results from three large previous cohort studies in the same part of Denmark, starting at different times. Researchers wanted to see if there had been a change over time in the optimal BMI score – that is, the BMI shared by people with the lowest rate of death from any cause.
	4. Dépistage, diagnostic et pronostic
NHS England to stream £15m into better cancer diagnosis [Pharma Times] The “major programme of work” includes the creation of a National Diagnostics Capacity Fund, which will test initiatives to increase capacity and productivity of diagnostic services.
	5. Traitements
Microwave Ablation for Treating Liver Metastases [ESMO] Current evidence on microwave ablation for treating liver metastases raises no major safety concerns and the evidence on efficacy is adequate in terms of tumour ablation. Therefore this procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit.
	5.2.1 Pharma - Partenariats
A Professor’s View On Drug Company Collaborations [In the Pipeline] In the past, pharmaceutical companies had more projects related to families of natural products (corticosteroids, betalactams, macrolides, prostaglandines) and the complex chemistry involved encouraged long term collaborations with academic groups. It seems now that companies want academics to just make new scaffolds or molecules for testing and this is less conducive to the discovery of new chemistry.
	5.2.3 Pharma - économie
After rivals’ IPOs, will CRISPR Therapeutics go public or stay buttoned-down? [STAT] CRISPR Therapeutics began in 2012 as a three-person operation called Inception Genomics, with Foy handling finances, former Sanofi executive Rodger Novak as CEO, and award-winning scientist Emmanuelle Charpentier contributing her game-changing discoveries in the science of CRISPR.
	5.3 Traitements - FDA, EMA,...
Industry Calls for More Guidance From FDA on New Clinical Trials Technology [RAPS] The use of smartphones and tablet devices to collect trial participant data is of particular interest to FDA as it's requesting more information on the challenges associated with collecting data on trial participants' own devices, which FDA says may be used to access and respond to study-related questionnaires.
Supporting innovative SMEs as major drivers of new pharmaceutical developments [EMA] The European Medicines Agency (EMA) has published today a report summarising the experience with its small and medium-sized enterprise (SME) initiative over the last ten years.
Can regulators influence the affordability of medicines? [EMA] Top EMA and national authority representatives discuss options in a NEJM article.
	5.3.4 Traitements - AMM (FDA, EMA)
Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy [BMS] Accelerated assessment and approval based on long-term data from ELOQUENT-2, which evaluated Empliciti in combination with Revlimid® (lenalidomide) and dexamethasone (Rd).
European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma [BMS] With this fifth EU approval for Opdivo, in three distinct tumor types, more patients fighting cancer have access to Immuno-Oncology treatment options in Europe.
AstraZeneca drug wins orphan status in thyroid cancer [Reuters] Selumetinib, which belongs to a class of cancer drugs known as MEK inhibitors, failed to meet its goal in a late-stage trial for uveal melanoma in July 2015. The drug is also being investigated as a treatment for advanced non-small cell lung cancer.
	5.4 Traitements - Economie
NICE turns down Opdivo for lung cancer [Pharma Times] The drug was available to patients with advanced lung cancer in the UK through the Early Access to Medicines Scheme prior to it’s European approval. NICE has since rejected Opdivo for patients with squamous NSCLC and for those with non-squamous NSCLC, leaving NHS patients with advanced lung cancer no route for accessing it outside of clinical trials.
Would A Wider Variety Of Vial Sizes Reduce The Cost Of Chemotherapy? Not Likely [Health Affairs] Pharmaceutical pricing is a tangled issue, requiring tough tradeoffs that are politically challenging. Unfortunately, we’re not likely to avoid those challenges with a clever shortcut.
	5.9 AACR
Advances in Pancreatic Cancer Research: Q&A With Christine Iacobuzio-Donahue, MD, PhD [CANCER RESEARCH Catalyst] This week, scientists from around the world will convene in Orlando, Florida, as the AACR hosts a conference titled Pancreatic Cancer: Advances in Science and Clinical Care. The conference will include discussion on the biological mechanisms of pancreatic cancer, drug development, epidemiology and risk factors, patient perspectives, and more.
	6. Lutte contre les cancers
The Improvisational Oncologist [NY Times] In an era of rapidly proliferating, precisely targeted treatments, every cancer case has to be played by ear.
	6.10 Politiques
Ex-FDA head and Sanofi call for harmonized drug regulation [Reuters] Margaret Hamburg, who led the FDA until 2015, and Elias Zerhouni said there was an urgent need to harmonize a "mosaic of regulations" in different countries, and they called for the issue to be taken up at the G8 or G20 groups of nations.
	6.6 Publications
NIH appoints Patricia Flatley Brennan, R.N., Ph.D., to lead the National Library of Medicine [NIH] Dr. Brennan has been a pioneer in the development of information systems for patients. She developed ComputerLink, an electronic network designed to reduce isolation and improve self-care among home care patients.
The pressure to publish pushes down quality [Nature News & Comment] By one estimate, 10,000 published papers a year cite work based on contaminated cancer cell lines. Metastasis has spread to the cancer literature.